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Novel ﬂuorescent chalcone-based ligands at human histamine H3 receptors (hH3R) have
been designed, synthesized, and characterized. Compounds described are non-imidazole
analogs of ciproxifan with a tetralone motif. Tetralones as chemical precursors and related
ﬂuorescent chalcones exhibit afﬁnities at hH3R in the same concentration range like the
reference antagonist ciproxifan (hH3R pK i value of 7.2). Fluorescence characterization of
our novel ligands shows emission maxima about 570 nm for yellow ﬂuorescent chalcones
and ≥600 nm for the red ﬂuorescent derivatives. Interferences to cellular autoﬂuores-
cence could be excluded. All synthesized chalcone compounds could be used to visualize
hH3R proteins in stably transfected HEK-293 cells using confocal laser scanning ﬂuores-
cence microscopy. These novel ﬂuorescent ligands possess high potential to be used as
pharmacological tools for hH3R visualization in different tissues.
Keywords: human histamine H3 receptor, fluorescent ligand, fluorescence confocal laser scanning microscopy,
pharmacological tool
INTRODUCTION
Histaminergic receptors belong to class A of membrane bound
G-protein-coupled receptors (GPCRs). They consist of four sub-
types, the histamine H1, H2, H3, and H4 receptors (Walter and
Stark, 2012). The H3 receptor has a neurotransmitter function.
High receptor densities could be found in different areas of the
central nervous system (Martinez-Mir et al., 1990; Sander et al.,
2008). Possible indications of H3 receptor antagonists/inverse ago-
nists could be the treatment of cognitive and sleep disorders
as well as schizophrenia, epilepsy, adipositas, and neuropathic
pain (Girard et al., 2004). To get information on etiopathol-
ogy and accumulation or depletion of human histamine H3
receptors (hH3R) and to accelerate the clinical development of
pharmaceuticals in the screening of drugs it is interesting to
design labeled H3 receptor ligands. To date several different tech-
niques have been used to measure receptor occurrence in tissues.
Radioactive competition is often used for instance in brain slices
with [3H](R)-alpha-methylhistamine (Martinez-Mir et al., 1990),
[3H]N α-methylhistamine (Le et al., 2009), [3H]-A-349821 (Miller
et al., 2009), [125I]iodoproxyfan (Ligneau et al., 1994; Stark et al.,
1996), and [125I]iodophenpropit (Jansen et al., 2000). Adversely,
analysis of ex vivo autoradioactivity often takes longer time (Le
et al., 2009) and synthesis and storage of radioligands causes
high costs and special equipment/rooms. Radioactive exposure
as generally known is very harmful. Fluorescent ligands are pre-
ferred over radioligands in terms of safety precautions and often
applicability. Fluorescent ligands and their use for the localiza-
tion and detection of GPCRs is still a topical area of investigation
(Kuder and Kiec-Kononowicz, 2008). Attempts to design ﬂuores-
cent human hH3R were established with motif structure elements
of Sangers reagent, dansyl, NBD, cyanoisoindol, and tetramethyl-
rhodamine groups (Amon et al., 2006, 2007; Cowart et al., 2006;
Kuder et al., 2010). Most of these compounds showed high afﬁnity
at histamineH3 receptors (hH3RK i: 0.1–10 nM),but their ﬂuores-
cence absorption and emission wavelengths were mainly between
300 and 500 nm. In this wavelength range interactions with cel-
lular autoﬂuorescence occur and in addition to this problem,
most of these ligands possess low ﬂuorescence intensities. A PhD
thesis from the working group of Prof. Buschauer (University
Regensburg,Erdmann,2010) presented further ﬂuorescent human
histamine H3 ligands. Applied ﬂuorophores possess good ﬂuo-
rescent features but are expensive or difﬁcult to synthesize. The
aim of this study was the optimization of the ﬂuorescent proper-
ties taking advantage of already published ﬂuorescent ligands as
lead structures. A literature survey indicated bio-active ﬂuorescent
benzylidine tetralones (Kamakshi et al., 2010) possessing different
antibacterial activity and useful physicochemical data (Al-Ansari,
1998). Tomecková et al. (2004) reported on related cyclic chalcone
analogs demonstrating biological effects on mitochondrial outer
membrane via ﬂuorescence microscopy. These results motivated
us to use chalcones as ﬂuorescent element for labeling of histamine
H3 receptor ligands to generate novel ﬂuorescent pharmaceutical
tools (Figure 1).
MATERIALS AND METHODS
CHEMISTRY
All reagents and solvents were purchased from VWR (Darm-
stadt,Germany), Sigma-Aldrich (Steinheim,Germany),AlfaAesar
(Ward Hill, MA, USA), Perkin Elmer Life and Analytical Sciences
(Rodgau, Germany), and Acros Organics (Geel, Belgium), and
were used without further puriﬁcation (unless otherwise stated).
1H and 13C NMR spectra were recorded on a AV 250 Spektrom-
eter (5.9 T; 1H: 250MHz; 13C: 63MHz), AV 300 Spektrometer
(7.1 T; 1H:300MHz; 13C: 75MHz),orAV400Spektrometer (0.4 T;
1H: 400MHz, 13C: 100MHz): Bruker (Rheinstetten, Germany).
Electro-spray-ionization MS (ESI MS) was performed on a: VG
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FIGURE 1 | Design strategy for novel fluorescent human histamine H3
receptor ligands.
Platform II: Fisons Instruments (Manchester, GB) and nano-ESI
(nESI): Mariner Workstation TOF: Applied Biosystems (Carlsbad,
CA, USA). High resolution MS (HRMS) was recorded on a LTQ
Orbitrap XL: Thermo Fisher Scientiﬁc (Waltham, MA, USA). Ele-
mental analyses (C, H, N) were measured on a Vario MicroCube:
ElementarHeraeus (Hanau,Deutschland) andwerewithin±0.4%
of the theoretical values for all ﬁnal compounds. Preparative col-
umn chromatography was performed on silica gel 60 F254, coat
thickness: 0.2mm (VWR, Darmstadt, Germany). The microwave
oven used was a Biotage Initiator 2.0 (400W): Biotage (Uppsala,
Sweden). For detailed synthesis procedures and analytical data see
Section “Appendix.”
The initializing precursor 3-(piperidin-1-yl)propan-1-ol
hydrochloride was synthesized by alkylation of piperidine with
3-chloropropan-1-ol as described in the literature (Apelt et al.,
2005) and chlorinated (Sander et al., 2010). 6-Hydroxy-1-tetralone
was commercially available whereas its regioisomer 7-hydroxy-1-
tetralone was prepared from the corresponding methoxy deriv-
ative (Scheme 1). Ether cleavage has been carried out with
para-toluenesulfonic acid and 1-butyl-3-methyl-1H -imidazolium
bromide as ionic liquid under microwave condition with yields
greater than 90% as described before (Boovanahalli et al., 2003).
Synthesis of compound 1 and 2 started with the alkylation of
6- and 7-hydroxy-1-tetralone with 1-(3-chloropropyl)piperidine
hydrochlorid (Scheme 1) by Williamson ether reaction, respec-
tively (Williamson, 1851). Compound 1 and 2 were converted
into ﬂuorescent chalcones (compound 3, 4, 5, and 6) via aldol
condensation with appropriate aldehyde.
Alkylation of 4-(hydroxymethyl)phenol with 1-(3-chloropro
pyl)piperidine hydrochlorid was the initializing step in the synthe-
sis of compounds with elongated spacer B (Scheme 2). Resulting
(4-(3-(piperidin-1-yl)propoxy)phenyl)methanol was chlorinated
with thionylchloride. After alkylation with 6- and 7-hydroxy-1-
tetralone ﬂuorescent chalcones were synthesized with correspond-
ing aldehydes (compounds 9–12), respectively. All tetralone and
chalcone derivatives were puriﬁed by column chromatography.
Oily products were crystallized as salts of oxalic acid in ethanol.
For ﬂuorescence characterization all corresponding histamine
H3 receptor ligands were dissolved in buffer (12.5mM MgCl2,
100mM NaCl, and 75mM Tris/HCl, pH 7.4) at a concentration
of 10mM. Fluorescence absorption and emission spectra were
recorded on a Fluorolog HORIBA JOBIN YVON ﬂuorometer
(HORIBA scientiﬁc, Kyoto, Japan) at room temperature. Spec-
tra were analyzed with FluorEssence™(HORIBA scientiﬁc, Kyoto,
Japan) for Windows®.
BINDING STUDIES
Determination of human histamine H3 receptor afﬁnity
HEK-293 cells stably expressing the recombinant human hista-
mine H3 receptor were used for membrane extraction. In brief,
membrane protein concentration was determined by the method
of Bradford (1976). Competition binding experiments were car-
ried out as described before (Kottke et al., 2011). Membranes were
incubated with [3H]N α-methylhistamine (2 nM) and test ligand
in a concentration range between 0.01 nM and 100 μM. For deter-
mination of non-speciﬁc binding 10μM of pitolisant was used.
All values are means of at least three independent measurements,
each in triplicates and on seven different concentrations. Bind-
ing data were analyzed by the software GraphPad Prism™(2000,
version 3.02, San Diego, CA, USA).
Determination of human histamine H1 receptor afﬁnity
CHO-K1 cells expressing the human histamine H1 receptor were
used for membrane extraction. In brief, human histamine H1
receptor radioligand competition binding assay was performed
as described before (Rossbach et al., 2011). Membranes were
incubated with 1 nM of [3H]pyrilamine and test ligand in a con-
centration range from 100 nM to 100μM. For determination of
non-speciﬁc binding 10μM of chlorpheniramine was used. All
values are means of at least two independent measurements, each
in triplicates and four different concentrations. Binding data were
analyzed by the software GraphPad Prism™(2000, version 3.02,
San Diego, CA, USA).
Determination of human histamine H4 receptor afﬁnity
Sf9 cells transiently expressing the human histamine H4 receptor
and co-expressed with G-protein Gαi/o and Gβ1γ2 subunits were
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SCHEME 1 | Synthesis of compounds 1–6. (a) para-Toluenesulfonic acid,
1-butyl-3-methyl-1H -imidazolium bromide, microwave irradiation, 160˚C, 1 h,
η=97%; (b), 1-(3-chloropropyl)piperidine hydrochlorid, K2CO3, KI, acetone,
60˚C, 48 h, η=71–94%; (c) 4-(dimethylamino)benzaldehyde, ethanol/water,
NaOH, RT, over night, η=63–85%; (d) 4-(dimethylamino)cinnamic aldehyde,
ethanol/water, NaOH, RT, over night, η=69–89%.
used for membrane extraction. Competition binding experiments
were carried out as described before (Kottke et al., 2011). Mem-
branes were incubated with 10 nM [3H]histamine and test ligand
in a concentration range from 0.01 nM to 100μM. Non-speciﬁc
binding was determined by using 10μM JNJ-7777120. All val-
ues are means of at least two independent measurements, each in
triplicates and four different concentrations. Binding data were
analyzed by the software GraphPad PrismTM (2000, version 3.02,
San Diego, CA, USA).
CELL CULTURE
Slides were coated with poly-d-lysine (50μg/mL, Sigma-Aldrich,
Steinheim, Germany) and cooled for 2 h. HEK-293 cells stably
expressing the recombinant human histamine receptor (mean
protein content: 10μg/mL; Bmax: 300–900 fmol/mg) were seeded
(100,000 cells/mL) and grown in 2mL of Dulbecco´s modiﬁed
Eagle´s medium (without phenol red) with 2mM glutamine,
10mM HEPES, 10% fetal bovine serum, and 10μL/mL peni-
cillin/streptomycin in an atmosphere of 5%CO2 at 37˚C for 48 h in
six-well plates with poly-d-lysine coated slides. The medium was
removed, and the slides were incubated with 3% BSA in buffer
(12.5mM MgCl2, 100mM NaCl, and 75mM Tris/HCl, pH 7.4)
for 30min at 37˚C. Afterward the slides were washed with PBS
buffer and incubated with 2mL 200 nM of appropriate ﬂuorescent
H3 ligand in buffer (12.5mM MgCl2, 100mM NaCl, and 75mM
Tris/HCl,pH7.4) for 1 h at 37˚C. The ligand solutionwas removed,
washed with PBS buffer, and the cells were ﬁxed in methanol for
20min at a temperature of −20˚C. After equilibration with PBS
buffer the nucleus was stained with 100 nM blue ﬂuorescent DAPI
(4′,6-diamidino-2-phenylindole; Kapuscinski, 1995). The slides
were mounted on cover slips with 30μL Mowiol. For reasons of
comparison HEK-293 cells were cultured as blind reference and
treated with respective ligand in a similar manner.
FLUORESCENCE MICROSCOPY
Cell preparations were ﬂuorescently visualized with a con-
focal laser scanning microscope (Leica TCS SP5, Wetzlar,
Germany). Fluorescence intensities were adjusted minimizing
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SCHEME 2 | Synthesis of compound 7–12. (a) K2CO3, KI, acetone, 60˚C, 48 h, η=65–71%; (b) 4-(dimethylamino)benzaldehyde, ethanol/water, NaOH, RT, over
night, η=85–91%; (c) 4-(dimethylamino)cinnamic aldehyde, ethanol/water, NaOH, RT, over night, η=93–95%.
autoﬂuorescence and all slices were measured with the same inten-
sity to generate comparable images. All images were recorded with
a 60× oil immersions objective. Fluorescence colors were adapted
to appropriate ﬂuorescence emission wavelengths. Fluorescent lig-
andswere excitedwith a 488 nmmultiline argon laser and emission
was detected between 520 and 790 nm. DAPI-stained nuclei of the
HEK-293 cells were excitedwith a 405 nmdiode laser and emission
was measured between 420 and 500 nm. Images were recorded in
sequential mode to avoid interferences.
RESULTS AND DISCUSSION
DESIGN OF NOVEL HUMAN HISTAMINE H3 LIGANDS
Historically the ﬁrst potent histamine H3 receptor ligands were
derivatized from the endogenous ligand histamine. Ciproxifan as
parent compound for these lead structures possesses a basic imi-
dazole ring as core moiety (Figure 1). Spacer A is a propyl group,
followed by a polar ether functionality linking the phenyl group
which is then connected to structurally different afﬁnity enhancing
elements. The imidazole-containing ciproxifan exerts an afﬁnity
at the human histamine H3 receptor in the medium nanomo-
lar concentration range (Table 1; Ligneau et al., 2000). Since the
imidazole group may potentially be associated with interaction
to the cytochrome P450 enzyme system, the change from imida-
zole to more robust piperidine systems in the western part of the
molecule has been performed resulting in an improved pharma-
cological proﬁle (Lazewska et al., 2006, 2008; Sander et al., 2008).
In 2001 the piperidine analog of ciproxifan, UCL-2190 (Figure 1),
was published (Meier et al., 2001). Likewise we introduced the
piperidine core element in our newly designed compounds, kept
spacerA constantwith threemethylene groups aswell as the benzyl
ether spacer. For compound 7–12 spacer B was elongated by the
benzyl ether. The keto group in the lipophilic residue of ciproxifan
was incorporated into a tetrahydronaphthalene system (1,2,7, and
8) which were converted to ﬂuorescent chalcones (3, 4, 5, 6, 9, 10,
11, and 12).
During design of novel ﬂuorescent pharmacological tools it is
important to generate compounds with high afﬁnity at the target
receptor, high ﬂuorescence intensities, and emission wavelengths
near the infrared wavelength range. It is difﬁcult to retain binding
afﬁnity and low molecular weight with structurally larger ﬂuo-
rophoric elements in small molecule GPCR ligands. Fluorophores
emitting with high wavelengths frequently consist of bulky struc-
tures. Al-Ansari (1998) and Kamakshi et al. (2010) described the
synthesis of unbulky, ﬂuorescent benzylidene tetralones which
have been used as ﬂuorophore lead element (Figure 1).
DETERMINATION OF HUMAN HISTAMINE H3 RECEPTOR AFFINITY
Afﬁnities of the newly designed ﬂuorescent chalcones (3, 4, 5, 6,
9, 10, 11, and 12) at the human histamine H3 receptor are in a
comparable nanomolar concentration range like that of ciproxi-
fan (Table 1). Tetralones with elongated aromatic spacer B exhibit
slightly lowerK i values than those of the shorter tetralones (1→ 7;
2→ 8) most probably due to increased lipophilic interactions.
Elongation of the tetralones with appropriate aldehydes gives no
further improvement in binding properties.
The variation from 6- to 7-hydroxy-1-tetralone derivatives
causes no remarkable difference in binding and does not result
in higher afﬁnities at the human histamine H3 receptor.
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Table 1 | Human histamine H1, H3, and H4 receptor affinities and fluorescence absorption and emission maximum wavelengths of novel
non-imidazole ligands.
Compound Structure hH1R K i
[nM]a
hH3R K i
[nM]b
hH4R K i [nM]c λmax Abs.
[nm]d
λmax Em.
[nm]d
Stokes
shift [nm]
Ciproxifan >10,000e 46±4f 612±32g
1 3,473±475 68±12 100,535±21,305
2 3,717±873 89±8 169,895±118,942
3 791±192 70±21 12,370±3,055 405 584 179
4 2,142±886 149±29 13,725±1,110 397 583 186
5 881±203 94±26 5,634±2,100 468 670 202
6 1,974±89 101±13 8,704±204 467 674 207
7 1,968±416 19±5 37,260±13,209
8 3,686±950 17±5 43,875±9,581
9 1,768±472 41±4 12,598±6,608 405 567 162
10 4,228±1,121 97±34 15,610±5,841 405 583 178
11 1,374±10 68±3 6,400±2,189 467 600 133
12 1,837±837 87±20 10,984±3,403 467 607 140
a[3H]Pyrilamine competition binding assay with membrane preparation of CHO-K1 cells expressing human histamine H1 receptor. b[3H]Nα-Methylhistamine competi-
tion binding assay with membrane preparation of HEK-293 cells over-expressing human histamine H3 receptor. c[3H]Histamine displacement assay with membrane
preparation of Sf9 cells transiently expressing human histamine H4 receptor and co-expressed with supporting G-Protein Gαi/o and Gβ1γ2. Ki values are means±SEM.
dMeasured in buffer (12.5mM MgCl2, 100mM NaCl, and 75mM Tris/HCl, pH 7.4) at a concentration of 10mM. eZhao et al. (2008). fLigneau et al. (2000). gGbahou
et al. (2006).
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DETERMINATION OF HUMAN HISTAMINE RECEPTOR SELECTIVITY
For selectivity validation the new compounds have been screened
on afﬁnity at related human histamine H1 and H4 receptors. All
ligands possess highest afﬁnity at the human histamine H3 recep-
tor demonstrating their receptor preference (Table 1). Afﬁnity at
the human H1 receptor is about one log unit and at the human
histamine H4 receptor about two log units higher than that at the
human histamine H3 receptor.
Compound 8 demonstrated one of the highest selectivity over
all 12 compounds. Compound 9 is the most selective compound
in the ﬂuorescent chalcone series whereas compound 5 the less
selective chalcone. These data further prove the beneﬁcial effects
of elongation of spacer B via benzyl ether concerning selectivity
and afﬁnity.
FLUORESCENCE CHARACTERIZATION
Kamakshi et al. (2010) described the ﬂuorophore lead structure
(Figure 1) as compound with intense emission signals. Absorp-
tion maximum was found at 406 nm. The ﬂuorophore lead is
described as charge transfer compound where the N,N -dimethyl
group behaves as the electron donor moiety and the carbonyl
group as the electron acceptor moiety. These two groups form a
donor–acceptor complex upon excitation. Fluorescence measure-
ment conﬁrmed the absorption maxima (compounds 3, 9, and 10:
405 nm; cf. Appendix).
Introduction of an additional vinyl group resulted in an
increased maximum in excitation and emission wavelength. (cf.
3→ 5: Δλmax Abs.: 63 nm, Δλmax Em.: 102 nm). Compounds
with propenone element (3, 4, 9, 10) emit in the yellow area of
the ﬂuorescence spectrum and compounds with pentadienone
elements (5, 6, 11, 12) in the red one. It is important to
design ﬂuorophores which emit ﬂuorescence higher than 500 nm.
In the blue spectroscopic area (300–450 nm) high autoﬂuores-
cence occurs and causes difﬁculties in detection of the actual
target. In ﬂuorescence visualization it is the aim to achieve
emission in the near infrared wavelength area to improve the
signal-to-noise ratio. Therefore it is a need to use ﬂuorophores
with high quantum yields and low quenching properties. To
avoid self-quenching it is important to synthesize ﬂuorophores
with large Stokes shifts. All compounds fulﬁll this requirement
(Table 1).
Elongation of spacer B via benzyl ether group causes decrease of
emission wavelengths of red emitting chalcones. Introduction of a
phenylether group can inﬂuence the donor–acceptor complex of
the ﬂuorophore. Elongated compounds show higher ﬂuorescence
emission intensities (Figure 2; cf. Appendix).
For the measurement of ﬂuorescence absorption and emis-
sion buffer (12.5mM MgCl2, 100mM NaCl, and 75mM Tris/HCl,
pH 7.4) has been used to simulate assay conditions and simul-
taneously ﬁnd the ideal settings for confocal laser microscope
studies.
VISUALIZATION OF HUMAN HISTAMINE H3 RECEPTORS
To minimize unspeciﬁc binding cells were incubated for 30min
with 3% BSA solution. Fluorescent histamine H3 receptor lig-
ands were added in a concentration range of two up to three
times of K i-value at the human histamine H3 receptor (200 nM)
FIGURE 2 | Fluorescence emission spectra of selected chalcone
derivatives.
on hH3-HEK-293 and HEK-293 cells. After washing steps and
staining of the nucleus with blue ﬂuorescent DAPI as reported in
literature (Kapuscinski, 1995), slides were ﬁxed with Mowiol and
analyzed with a confocal laser scanning microscope (Figure 3).
Chalcones synthesized from 4-(dimethylamino)benzaldehyde
result in yellow ﬂuorescent ligands like compound 3 and 9.
Chalcones synthesized from 4-(dimethylamino)cinnamic alde-
hyde in red emitting ligands like compound 5. Due to their
maximum emission wavelengths ligand color on the confocal
laser scanning microscope was adjusted. Fluorescence images were
recorded in sequential mode to avoid interfering of emission
wavelengths of ligand and DAPI ﬂuorescence. In the ﬁrst step
DAPI-stained nuclei were recorded (Figures 3B,E,H,K) between
420 and 500 nm, then ﬂuorescent ligand emission was measured
between 520 and 790 nm (Figures 3A,D,G,J). Appropriate images
were over-laid to co-localize ﬂuorescent ligand and ﬂuorescent
nucleus (Figures 3C,F,I,L). Figure 3D shows the enrichment
of the yellow emitting compound 3 in the outer membrane of
hH3-HEK-293 cells. Figure 3G shows the enrichment in same
regions in hH3-HEK-293 cells of the red emitting compound 5
which emits more intensive (Figure 2). The most human hist-
amine H3 receptor selective and most intense compound (9) is
shown in Figures 3J–L. Fluorescent human histamine H3 ligands
stain the outer membrane of hH3-HEK-293 cells where human
hH3R are mainly expressed. In HEK-293 cells which do not have
human hH3R, no enrichment of ligand in the outer cell mem-
brane can be identiﬁed (Figures 3A,C; cf. Appendix) indicating
selectivity to the aimed receptor (Table 1). The ﬂuorescent lig-
ands on HEK-293 cells are diffusely distributed and emit in a
low manner if compared to images 3D, 3G, and 3J where outer
membranes emit strong ﬂuorescence (cf. Appendix). Differences
between hH3- and HEK-293 cells are facile to detect. Fluores-
cence emission of chalcone derivatives on HEK-293 cells is in
the same range as autoﬂuorescence (cf. Appendix) and therefore
negligible.
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FIGURE 3 | Confocal laser scanning microscope images of fluorescent
human histamine H3 ligands on HEK-293 cells and hH3-HEK-293. All
images were taken on a Leica TCS SP5 microscope. Fluorescent chalcones
were incubated for 1 h and after washing steps nuclei were stained with
blue ﬂuorescent DAPI. (A) Shows a HEK-293 cell labeled with compound 3
and (B) shows the DAPI-stained nucleus of the same cell. (C) Is an overlay
of image (A,B). (D) Shows compound 3 on an hH3-HEK-293 cell, (E) the
DAPI-stained nucleus of the same cell and (F) an overlay of (D) and (E). Red
ﬂuorescent compound 5 on an hH3-HEK-293 cell is shown in (G), cell
nucleus in (H), and the overlay of (G) and (H) in (I). (J) Shows an
hH3-HEK-293 cell stained with compound 9, (K) its nucleus, and (L) the
overlay of (J,K).
CONCLUSION
In our work we achieved the design of selective and ﬂuorescent
human histamine H3 receptor ligands. Afﬁnities at the human his-
tamine H3 receptor of all newly synthesized compounds are in the
nanomolar concentration range. All 12 compounds showed high
H3 receptor preference in comparison to their binding properties
at H1 and H4 receptors.
The ﬂuorescent chalcone ligands facilitate visualization of
human hH3R on hH3–HEK cells. Their ﬂuorescence character-
istics (ﬂuorescence emission maxima higher than 500 nm) avoid
appearance of interference with autoﬂuorescence. Intense light
signals label the localization of targeted receptor. Reference HEK-
293 cells which do not over-express human hH3R show negligi-
ble binding of ﬂuorescent ligands demonstrating low unspeciﬁc
binding.
Compounds 3, 5, and 9 showed excellent, but slightly diverse
properties concerning absorption, emission, Stokes shift, inten-
sity and H3 receptor afﬁnity and selectivity. Best compound
concerning wavelength represents compound 5 (λmax Abs./Em.:
468/670 nm) but it is not as selective as compound 9 which emits
with highest intensity of all synthesized compounds in the yel-
low area of spectrum. Compound 9 has the highest afﬁnity at the
human histamine H3 receptor compared to the other chalcone
derivatives in this series.
Our new ﬂuorescent ligands open new possibilities for non-
radioactive alternatives for novel binding assays and novel visual-
ization tools. They are precious tools for detailed pharmacological
analyses on detection of receptors in cells and tissues. Studies on
different tissues with these novel ligands are envisaged to provide
further evidence of their convenience as pharmacological tools.
More detailed information is available in the Appendix.
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APPENDIX
CHEMICAL ANALYSIS OF SYNTHESIZED COMPOUNDS
NMR chemical shifts (δ) are reported in ppm downﬁeld from
tetramethylsilane as internal reference.Multiplicities of peaks have
following abbreviations: br, broad; s, singlet; d, doublet; dd, double
doublet; t, triplet; m, multiplet; q, quintet. Coupling constants are
given in Hertz (Hz). Numbers and assignments of protons or car-
bon atoms are named: ox, oxalate; pip, piperidine; ph, phenyl;
prop, propyl; tetr, tetralone; dmab, 4-(dimethylamino)benzyl;
dmap, 4-(dimethylamino)phenyl; benzylid, benzylidene; allylid,
allyllidene.
3-(Piperidin-1-yl)propan-1-ol hydrochloride
Piperidine (47.4 g, 0.56mol), 3-chloropropan-1-ol (35.1 g,
0.37mol), potassium carbonate (77.0 g, 0.56mol) and potas-
sium iodide (61.6 g, 0.37mol) were reﬂuxed in absolute acetone
(300mL) for 72 h under inert atmosphere. The mixture was
allowed to cool to room temperature, inorganic components were
removed by ﬁltration and the ﬁltrate was concentrated to dry-
ness. The crude oil was further puriﬁed by distillation (10 mbar,
88˚C). The oily product was crystallized as hydrochloride from
isopropanolic HCl. White solid, 54.1 g, 81%.
C8H17NO×HCl
Molecular weight: 179.7
1H NMR (300MHz, DMSO-d6) δ 10.59 (br s, 1H, NH+), 4.39
(s, 1H, OH ), 3.46 (t, J= 5.9, 2H, prop-1H2), 3.36–3.31 (m, 2H,
pip-2,6H eq), 3.01–2.94 (m, 2H, prop-3H2), 2.84–2.80 (m, 2H,
pip-2,6H ax), 1.86–1.66 (m, 7H, prop-2H2, pip-3,5H2, pip-4H eq),
1.42–1.28 (m, 1H, pip-4H ax).
13C NMR (75MHz, DMSO-d6) δ 57.99 (prop-1C), 53.49
(prop-3C), 52.99 (pip-2,6C), 26.36 (prop-2C), 22.18 (pip-3,5C),
21.33 (pip-4C).
ESI MS: 143.8 [M+H+] (100).
1-(3-Chloropropyl)piperidine hydrochloride
3-(Piperidin-1-yl)propan-1-ol hydrochloride (35.3 g,0.2mol)was
suspended in toluene (100mL) an excess of thionyl chloride
(28.5mL, 0.4mol) was added dropwise at a temperature of 0˚C
under inert atmosphere. After beginning of the exothermic reac-
tion the mixture was stirred for 3 h at 60˚C. Thionyl chloride and
toluene were distilled off. The beige product crystallized during
the reaction and could be ﬁltered off. Beige solid, 38.1 g, 98%.
C8H16ClN×HCl
Molecular weight: 198.1
1H NMR (300MHz, DMSO-d6) δ 10.69 (br s, 1H, NH+), 3.68
(t, J= 6.4, 2H, prop-3H2), 3.41–3.36 (m, 2H, pip-2,6H eq), 3.11–
3.04 (m, 2H,prop-1H2), 2.94–2.81 (m, 2H,pip-2,6H ax), 2.31–2.22
(m, 2H, prop-2H2), 1.77–1.60 (m, 5H, pip-3,5H2, pip-4H eq),
1.39–1.28 (m, 1H, pip-4H ax).
13C NMR (75MHz,DMSO-d6) δ 54.14 (prop-3C), 52.01 (pip-
2,6C), 41.44 (prop-1C), 25.19 (prop-2C), 23.08 (pip-3,5C), 22.31
(pip-4C).
ESI MS: 161.6 [M+H+] (100).
Compound 1
6-(3-(Piperidin-1-yl)propoxy)-1-tetralone. 1-(3-Chloropropyl)
piperidine hydrochloride (1 g, 5.1mmol), 6-hydroxy-1-tetralone
(0.9 g, 5.6mmol), potassium carbonate (2.3 g, 16.7mmol) and
potassium iodide (0.9 g, 5.6mmol) were reﬂuxed in absolute ace-
tone (100mL) for 72 h under inert atmosphere. After cooling to
room temperature inorganic salts were ﬁltered off. The ﬁltrate was
concentrated todryness and resuspended indichloromethane.The
organic layer was washed three times with 2M NaOH solution and
brine, dried with MgSO4, and concentrated to dryness. Resulting
brown oil was crystallized with waterfree oxalic acid in absolute
ethanol. Beige crystals were ﬁltered off. Beige solid, 1.4 g, 71%.
C18H25NO2 × (COOH)2 × 0.25 H2O
Molecular weight: 381.9
1H NMR (400MHz, DMSO-d6) δ 7.83 (d, J = 8, 1H, tetr-8H ),
6.90 (m, J = 12, 2H, tetr-5,7H ), 4.09 (t, J= 8, 2H, prop-3H2),
2.91 (t, J= 8, 2H, tetr-2H2), 2.52 (t, J= 9, 2H, tetr-4H2), 2.38 (t,
2H, J= 8, prop-1H2), 2.36–2.34 (m, 4H, pip-2,6H 2), 2.01 (q, 2H,
J = 8, tetr-3H2), 1.88 (q, 2H, J = 7, prop-2H2), 1.54–1.46 (m, 4H,
pip-3,5H 2), 1.43–1.35 (m, 2H, pip-4H 2).
13C NMR (100MHz, DMSO-d6) δ 196.04 (tetr-1C), 164.40
(ox-COOH), 162.53 (tetr-7C), 147.18 (tetr-8aC), 128.67 (tetr-
8C), 125.63 (tetr-4aC), 113.58 (tetr-5C), 113.08 (tetr-7C), 66.24
(prop-3C), 54.96 (prop-1C), 54.08 (pip-2,6C), 38.38 (tetr-2C),
29.27(tetr-4C), 26.13 (prop-2C), 25.57 (pip-3,5C), 24.10 (pip-
4C), 22.93 (tetr-3C).
ESI MS: 288.52 [M+H+] (100).
Anal. calc.: C, 62.89; H, 7.26; N, 3.67. Found: C, 62.91; H, 7.41;
N, 3.58.
7-Hydroxy-1-tetralone. 7-Methoxy-1-tetralone (1 g, 5.7mmol),
para-toluenesulfonic acid (3.2 g, 17.0mmol), and 1-butyl-3-
methyl-1H -imidazol-3-ium bromide (12.2 g, 34.1mmol) were
mixed in a 20mL microwave vial. Mixture was heated for 1 h
for 160˚C under microwave condition. After cooling down to
room temperature the reaction mixture was diluted with water
and extracted three times with ethyl acetate. The organic phase
was washed with brine, dried with MgSO4, and concentrated to
dryness. Resulting yellowish crystals were used without further
puriﬁcation. Yellowish solid, 0.9 g, 97%.
C10H10O2
Molecular Weight: 162.1
1HNMR (250MHz,DMSO-d6) δ 9.58 (s, 1H,OH ), 7.25 (s, 1H,
tetr-8H ), 7.19 (d, J = 10, 1H, tetr-5H ), 6.98 (d, J = 10, 1H, tetr-
6H ), 2.83 (t, J = 7.5, 2H, tetr-4H2), 2.55 (t, J = 7.5, 2H, tetr-2H2),
2.00 (q, J = 6.3, 2H, tetr-3H2).
13C NMR (63MHz, DMSO-d6) δ 197.48 (tetr-1C), 155.86
(tetr-7C), 135.27 (tetr-4aC), 133.06 (tetr-8aC), 130.18 (tetr-
5C), 121.10 (tetr-6C), 111.80 (tetr-8C), 38.30 (tetr-2C), 28.12
(tetr-4C), 23.25 (tetr-3C).
ESI MS: 160.5 [M−H+] (100).
Compound 2
7-(3-(Piperidin-1-yl)propoxy)-1-tetralone. 1-(3-Chloropropyl)
piperidine hydrochloride (1.55 g, 7.9mmol), 7-hydroxy-1-tet
ralone (1.4 g, 8.6mmol), potassium carbonate (3.6 g, 25.9mmol),
and potassium iodide (1.4 g, 8.6mmol) were reﬂuxed in absolute
acetone (50mL) for 72 h under inert atmosphere. After cooling
to room temperature inorganic salts were ﬁltered off. The ﬁltrate
was concentrated to dryness and resuspended in dichloromethane.
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The organic layer was washed three times with 2MNaOH solution
and brine, dried with MgSO4, and concentrated to dryness. Beige
crystals, 2.1 g, 94%.
C18H25NO2
Molecular Weight: 287.4
1HNMR(250MHz,DMSO-d6) δ 7.34 (s, 1H, tetr-8H ), 7.29 (d,
J = 7.5, 1H, tetr-5H ), 7.16 (d, J = 7.5, 1H, tetr-6H), 4.02 (t, J = 5,
2H, prop-1H2), 2.87 (t, J= 6.25, 2H, tetr-4H2), 2.59 (t, J= 6.25,
2H, tetr-2H2), 2.38 (t, 2H, J= 5,prop-3H2), 2.35–2.31 (m,4H,pip-
2,6H 2), 2.02 (q, 2H, J = 5, tetr-3H2), 1.86 (q, 2H, J = 7,prop-2H2),
1.54–1.48 (m, 4H, pip-3,5H 2), 1.41–1.34 (m, 2H, pip-4H 2).
13C NMR (63MHz, DMSO-d6) δ 197.38 (tetr-1C), 157.35
(tetr-7C), 137.14 (tetr-4aC), 133.18 (tetr-8aC), 130.60 (tetr-5C),
122.08 (tetr-6C), 109.99 (tetr-8C), 66.39 (prop-1C), 55.09 (prop-
3C), 54.10 (pip-2,6C), 38.45 (tetr-2C), 27.94 (tetr-4C), 26.56
(prop-2C), 25.60 (pip-3,5C), 24.10 (pip-4C), 23.09 (tetr-3C).
ESI MS: 288.6 [M+H+] (100).
HRMS: calc.: 288.19581; found: 288.19633.
Compound 3
(E)-2-(4-(Dimethylamino)benzylidene)-6-(3-(piperidin-1-yl)
propoxy)-1-tetralone. Compound 1 (500mg, 1.7mmol) and 4-
(dimethylamino)benzaldehyde (260mg,1.7mmol)were dissolved
in 5mL ethanol. 15M NaOH (0.25mL) was added. The mixture
was stirred over night at room temperature, concentrated to dry-
ness, and puriﬁed by column chromatography (CH2Cl2/MeOH,
9/1). The oily product was crystallized with waterfree oxalic acid
in absolute ethanol. Crystals were ﬁltered off. Yellow solid, 582mg,
63%.
C27H34N2O2 × (COOH)2 × 1.25 H2O
Molecular weight: 530.78
1H NMR (400MHz, DMSO-d6) δ 7.92 (d, J = 8, 1H, tetr-8H ),
7.63 (s, 1H, benzylid-2H ), 7.45 (d, J = 8, 2H,dmab-2,6H ), 6.95 (d,
J = 8, 1H, tetr-7H ), 6.90 (s, 1H, tetr-5H ), 6.79 (d, J = 8, 2H,dmab-
3,5H ), 4.16 (t, J= 12, 2H,prop-3H2), 3.12–3.08 (m,6H,prop-1H2,
pip-2,6H 2), 3.00 (s, 6H, dmab-N(CH3)), 2.96 (t, J= 9, 2H, tetr-
4H2), 2.92 (q, J= 8, 2H, tetr-3H2), 2.15 (q, J = 7, 2H, prop-2H2),
1.80–1.69 (m, 4H, pip-3,5H 2), 1.61–1.41 (m, 2H, pip-4H 2).
13C NMR (100MHz, DMSO-d6) δ 196.12 (tetr-1C), 164.32
(ox-COOH), 161.87 (tetr-7C), 150.52 (dmab-4C), 145.45 (tetr-
8aC), 136.37 (benzylid-2C), 132.05 (tetr-2C), 131.84 (dmab-
2,6C), 129.67 (tetr-8C), 126.64 (tetr-4aC), 122.64 (dmab-1C),
113.77 (tetr-5C), 112.72 (tetr-7C), 111.68 (dmab-3,5C), 65.30
(prop-3C), 53.40 (prop-1C), 52.28 (pip-2,6C), 40.12 (dmab-
N(CH3)2), 28.18(tetr-4C), 26.82 (prop-2C), 23.54 (pip-4C),
22.78 (pip-3,5C), 21.53 (tetr-3C).
ESI MS: 419.6 [M+H+] (100).
Anal. calc.: C, 65.58; H, 7.31; N, 5.27. Found: C, 65.63; H, 6.92;
N, 5.27.
Compound 4
(E)-2-(4-(Dimethylamino)benzylidene)-7-(3-(piperidin-1-yl)
propoxy)-1-tetralone. Compound 2 (500mg, 1.7mmol) and
4-(dimethylamino)benzaldehyde (260mg, 1.7mmol) were dis-
solved in 7mL ethanol. 15M NaOH (0.25mL) was added.
The mixture was stirred over night at room temperature,
concentrated to dryness, and puriﬁed by column chromatography
(CH2Cl2/MeOH, 9/1). Yellow solid, 619mg, 85%.
C27H34N2O2
Molecular Weight: 418.6
1H NMR (250MHz, DMSO-d6) δ 7.67 (s, 1H, benzylid-2H ),
7.47 (d, J = 10, 2H, dmab-3,5H ), 7.42 (s, 1H, tetr-8H ), 7.30 (d,
J = 7.5, 1H, tetr-5H ), 7.16 (d, J = 8.75, 1H, tetr-6H ), 6.79 (d,
J = 7.5, 2H, dmab-2,6H ), 4.06 (t, J= 7.5, 2H, prop-3H2), 3.09
(t, J = 6.25, 2H, tetr-3H2), 2.99 (s, 6H, dmab-N(CH3)), 2.86 (t,
J= 7.5, 2H, tetr-4H2), 2.62–2.52 (m, 6H, prop-3H2, pip-2,6H2),
1.99 (q, 2H, J = 9, prop-2H2), 1.65–1.56 (m, 4H, pip-3,5H 2),
1.48–1.41 (m, 2H, pip-4H 2).
13C NMR (63MHz, DMSO-d6) δ 186.24 (tetr-1C),157.44
(tetr-7C), 150.68 (dmab-4C), 137.24 (benzylid-2C), 134.30 (tetr-
8aC), 131.91 (dmab-2,6C), 130.96 (tetr-4aC), 130.34 (tetr-5C),
122.63 (dmab-1C), 117.11 (tetr-6C), 111.93 (dmab-3,5C), 110.60
(tetr-8C), 65.94 (prop-1C), 54.54 (prop-3C), 53.21 (pip-2,6C),
39.53 (dmab-N(CH3)2), 27.37 (pip-3,5C), 26.12 (tetr-4C), 25.47
(prop-2C), 24.32 (pip-4C), 23.18 (tetr-3C).
ESI MS: 419.7 [M+H+] (100).
HRMS: calc.: 419.26930; found: 419.26971.
Compound 5
(E)-2-((E)-3-(4-(Dimethylamino)phenyl)allylidene)-6-(3-
(piperidin-1-yl)propoxy)-1-tetralone. Compound 1 (500mg,
1.7mmol) and 4-(dimethylamino)cinnamic aldehyde (305mg,
1.7mmol) were dissolved in 3mL ethanol. 15M NaOH (0.5mL)
was added. The mixture was stirred over night at room tempera-
ture, concentrated to dryness, and puriﬁed by column chromatog-
raphy (CH2Cl2/MeOH, 9/1). The oily product was crystallized
with ethanol. Crystals were ﬁltered off. Red solid, 545mg, 69%.
C29H36N2O2×0.5 H2O
Molecular weight: 453.6
1H NMR (400MHz, DMSO-d6) δ 7.90 (d, J = 8, 1H, tetr-8H ),
7.52 (d, J = 16, 1H, allylid-2H ), 7.31 (d, J = 8, 2H, dmap-2,6H ),
6.95 (d, J = 8, 1H, tetr-7H ), 6.94 (d, J= 16, 1H, allylid-4H ), 6.91
(s, 1H, tetr-5H ), 6.80 (d, J = 8, 2H, dmap-3,5H ), 6.50 (t, J = 16,
1H, allylid-3H ), 4.13 (t, J= 12, 2H, prop-3H2), 2.99 (s, 6H, dmap-
N(CH3)), 2.97–2.93 (m, 6H, prop-1H2, pip-2,6H 2), 2.47–2.31 (m,
4H, tetr-3H2, tetr-4H2), 1.96 (q, 2H, J = 7, prop-2H2), 1.56–1.48
(m, 4H, pip-3,5H 2), 1.46–1.36 (m, 2H, pip-4H 2).
13C NMR (100MHz, DMSO-d6) δ 196.08 (tetr-1C), 162.37
(tetr-7C), 149.33 (dmap-4C), 144.58 (tetr-8aC), 141.31 (allylid-
2C), 138.02 (allylid-4C), 135.99 (tetr-2C), 133.04 (dmap-2,6C),
129.06 (tetr-8C), 127.02 (tetr-4aC), 125.56 (allylid-3C), 121.97
(dmap-1C), 112.57 (tetr-5C), 112.21 (tetr-7C), 111.08 (dmap-
3,5C), 64.98 (prop-3C), 52.27 (prop-1C), 51.98 (pip-2,6C),
40.32 (dmab-N(CH3)2), 28.88 (tetr-4C), 26.31 (prop-2C), 23.40
(pip-4C), 22.18 (pip-3,5C), 21.55 (tetr-3C).
ESI MS: 445.74 [M+H+] (100).
Anal. calc.: C, 76.79; H, 8.22; N, 6.18. Found: C, 76.71; H, 8.47;
N, 5.90.
Compound 6
(E)-2-((E)-3-(4-(Dimethylamino)phenyl)allylidene)-7-(3-
(piperidin-1-yl)propoxy)-1-tetralone. Compound 2 (500mg,
1.74mmol) and 4-(dimethylamino)cinnamic aldehyde (305mg,
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1.74mmol) were dissolved in 3mL ethanol. 15M NaOH (0.5mL)
was added. The mixture was stirred over night at room tempera-
ture, concentrated to dryness, and puriﬁed by column chromatog-
raphy (CH2Cl2/MeOH, 9/1). Red solid, 689mg, 89%.
C29H36N2O2
Molecular Weight: 444.6
1H NMR (250MHz, DMSO-d6) δ 7.53 (d, J = 7.5, 1H, allyl-
2H ), 7.43–7.36 (m, 3H, dmap-2,6H, tetr-8H ), 7.28 (d, J = 7.5, 1H,
tetr-5H ), 7.18–7.12 (m, 2H, tetr-6H, allylid-4H ), 6.80 (t, J = 16,
1H, allyl-3H ), 6.74 (d, J = 10, 2H, dmap-3,5H ), 4.07 (t, J= 6.25,
2H, prop-1H2), 3.09 (t, J = 6.25, 2H, tetr-3H2), 2.98 (s, 6H, dmap-
N(CH3)), 2.87 (t, J= 7.5, 2H, tetr-4H2), 2.74–2.60 (m, 6H, prop-
3H2, pip-2,6H2), 2.01 (q, J = 9, 2H, prop-2H2), 1.68–1.54 (m, 4H,
pip-3,5H 2), 1.52–1.40 (m, 2H, pip-4H 2).
13C NMR (63MHz, DMSO-d6) δ 185.72 (tetr-1C), 157.42
(tetr-7C), 151.24 (dmap-4C), 142.62 (allylid-2C), 137.31 (allylid-
4C), 134.41 (tetr-8aC), 130.92 (tetr-4aC), 129.71 (tetr-5C), 128.98
(dmap-2,6C), 124.22 (allylid-3C), 120.54 (dmap-1C), 118.97
(tetr-6C), 112.03 (dmap-3,5C), 110.64 (tetr-8C), 65.97 (prop-
1C), 54.54 (prop-3C), 53.41 (pip-2,6C), 40.29 (dmap-N(CH3)2),
28.86 (tetr-4C), 27.17 (prop-2C), 25.86 (pip-3,5C), 24.74 (pip-
4C), 23.24 (tetr-3C).
ESI MS: 445.7 [M+H+] (100).
HRMS: calc.: 445.28495; found: 445.28500.
(4-(3-(Piperidin-1-yl)propoxy)phenyl)methanol. 1-(3-Chloropr
opyl)piperidine hydrochloride (4 g, 20.2mmol), 4-hydroxybenzyl
alcohol (2.5 g,22.2mmol),potassiumcarbonate (8.3 g,60.6mmol),
and potassium iodide (1.7 g, 20.2mmol) were reﬂuxed in absolute
acetone (100mL) for 72 h under inert atmosphere. After cooling
to room temperature inorganic salts were ﬁltered off. The ﬁltrate
was concentrated to dryness and resuspended in dichloromethane.
The organic layer was washed three times with 2M NaOH solu-
tion and brine, dried with MgSO4, and concentrated to dryness.
Yellowish solid, 3.6 g, 72%.
C15H23NO2
Molecular weight: 249.4
1H NMR (250MHz, DMSO-d6) δ 7.29 (d, J = 10, 2H, ph-
2,6H ), 6.96 (d, J = 10, 2H, ph-3,5H ), 5.12 (t, J= 7, 1H, OH ), 4.49
(d, J = 10, 2H, CH2-OH), 4.03 (t, J = 7.5, 2H, prop-1H2), 2.42
(t, J = 7.5, 2H, prop-3H2), 2.37–2.28 (m, 4H, pip-2,6H2), 1.93 (q,
J = 6.26, 2H, prop-2H2), 1.60–1.49 (m, 4H, pip-3,5H 2), 1.49–1.38
(m, 2H, pip-4H 2).
13C NMR (63MHz, DMSO-d6) δ 157.45 (ph-4C), 134.30 (ph-
1C), 127.95 (ph-2,6C), 113.93 (ph-3,5C), 66.01 (prop-1C), 62.75
(CH2-OH), 55.25 (prop-3C), 54.11 (pip-2,6C), 26.57 (prop-2C),
25.26 (pip-3,5C), 23.80 (pip-4C).
ESI MS: 250.46 [M+H+] (100).
1-(3-(4-(Chloromethyl)phenoxy)propyl)piperidine hydrochlo
ride. (4-(3-(Piperidin-1-yl)propoxy)phenyl)methanol (3.6 g,
14.5mmol) was dissolved in 100mL toluene and an excess of
thionyl chloride (3.2mL, 43.6mmol) was added dropwise at
0˚C under inert atmosphere. Once the exothermic reaction had
decayed the mixture was stirred for 3 h at 60˚C. Afterward
toluene and thionylchloride was distilled off. Crude product was
re-crystallized in ethanol. Beige solid, 4.1 g, 93%.
C15H22ClNO×HCl
Molecular weight: 304.3
1H NMR (250MHz, DMSO-d6) δ 10.62 (br s, 1H, NH+), 7.42
(d, J = 15, 2H, ph-2,6H ), 6.99 (d, J = 15, 2H, ph-3,5H ), 4.73
(s, 2H, CH2-Cl), 4.07 (t, J = 10, 2H, prop-1H2), 3.45 (t, J = 10,
2H, prop-3H2), 3.21–3.11 (m, 2H, pip-2,6Heq), 2.94–2.81 (m, 2H,
pip-2,6Hax), 1.91 (q, J = 6.26, 2H, prop-3H2), 1.69–1.50 (m, 5H,
pip-3,5H 2, pip-4Heq), 1.49–1.38 (m, 1H, pip-4Hax).
13C NMR (63MHz, DMSO-d6) δ 158.38 (ph-4C), 130.35 (ph-
2,6C), 130.33 (ph-1C), 114.58 (ph-3,5C), 65.35 (prop-1C), 53.44
(prop-3C), 51.86 (pip-2,6C), 46.08 (CH2-Cl), 23.30 (prop-2C),
22.43 (pip-3,5C), 21.55 (pip-4C).
ESI MS: 268.42 [M+H+] (100), 571.78 [2M+HCl] (19).
Compound 7
6-(4-(3-(Piperidin-1-yl)propoxy)benzyloxy)-1-tetralone. 1-(3-
(4-(Chloromethyl)phenoxy)propyl)piperidine hydrochloride
(1.7 g, 5.6mmol), 6-hydroxy-1-tetralone (1.0 g, 6.2mmol), potas-
sium carbonate (2.6 g, 18.5mmol) and potassium iodide (1.0 g,
6.2mmol) were reﬂuxed in absolute acetone (70mL) for 72 h
under inert atmosphere. After cooling to room temperature inor-
ganic salts were ﬁltered off. The ﬁltrate was concentrated to dry-
ness and resuspended in dichloromethane. The organic layer was
washed three times with 2M NaOH solution and brine, dried with
MgSO4, and concentrated to dryness. Beige solid, 1.4 g, 65%.
C25H31NO3
Molecular weight: 393.5
1H NMR (250MHz, DMSO-d6) δ 7.84 (d, J = 7.5, 1H, tetr-
8H ), 7.42 (d, J = 7.5, 2H, ph-2,6H ), 6.99–6.93 (m, 4H, ph-3,5H,
tetr-5H, tetr-7H ), 5.11 (s, 2H, ph-CH2), 4.06 (t, J = 6.3, 2H, prop-
1H2), 3.11–3.04 (m,6H,prop-3H2, pip-2,6H2), 2.90 (t, J = 6.3,2H,
tetr-2H2), 2.53 (t, J = 6.3, 2H, tetr-4H2), 2.15–1.96 (m, 4H, tetr-
3H2, prop-2H2), 1.73–1.69 (m, 4H, pip-3,5H 2), 1.55–1.53 (m, 2H,
pip-4H2).
13C NMR (63MHz, DMSO-d6) δ 196.37 (tetr-1C), 162.30
(tetr-6C), 158.39 (ph-4C), 147.23 (tetr-8aC), 130.00 (ph-2,6C),
128.63 (tetr-8C, ph-1C), 126.08 (tetr-4aC), 114.93 (ph-3,5C),
113.56 (tetr-5C), 113.54 (tetr-7C), 69.50 (prop-1C), 65.39 (ph-
CH2), 53.84 (prop-3C), 52.67 (pip-2,6C), 38.93 (tetr-2C), 29.17
(tetr-4C), 24.28 (prop-2C), 23.11 (pip-3,5C), 23.09 (pip-4C),
21.73 (tetr-3C).
ESI MS: 394.7 [M+H+] (100).
HRMS: calc.: 394.23767; found: 394.23800.
Compound 8
7-(4-(3-(Piperidin-1-yl)propoxy)benzyloxy)-1-tetralone. 1-(3-
(4-(Chloromethyl)phenoxy)propyl)piperidine hydrochloride
(2.4 g, 7.9mmol), 7-hydroxy-1-tetralone (1.4 g, 8.6mmol), potas-
sium carbonate (3.6 g, 25.9mmol) and potassium iodide (1.4 g,
8.6mmol) were reﬂuxed in absolute acetone (300mL) for 72 h
under inert atmosphere. After cooling to room temperature inor-
ganic salts were ﬁltered off. The ﬁltrate was concentrated to dry-
ness and resuspended in dichloromethane. The organic layer was
washed three times with 2M NaOH solution and brine, dried with
MgSO4, and concentrated to dryness. Beige solid, 2.2 g, 71%.
C25H31NO3
Molecular Weight: 393.5
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1H NMR (250MHz, DMSO-d6) δ 7.34 (s, 1H, tetr-8H ), 7.33
(d, J = 10, 2H, ph-2,6H ), 7.23 (d, J = 7.5, 1H, tetr-5H ), 7.15
(d, J = 7.5, 1H, tetr-6H), 6.90 (d, J = 10, 2H, ph-3,5H ), 5.00
(s, 2H, ph-CH2), 3.97 (t, J = 5, 2H, prop-1H2), 2.80 (t, J= 7.5,
2H, tetr-4H2), 2.50 (t, J= 7.5, 2H, tetr-2H2), 2.46–2.40 (m, 6H,
prop-3H2, pip-2,6H 2), 2.02 (q, 2H, J = 5, tetr-3H2), 1.92 (q, 2H,
J = 7, prop-2H2), 1.68–1.61 (m, 4H, pip-3,5H 2), 1.52–1.43 (m,
2H, pip-4H 2).
13C NMR (63MHz,DMSO-d6) δ 197.29 (tetr-1C), 157.88 (ph-
4C), 156.80 (tetr-7C), 137.10 (tetr-4aC), 133.03 (tetr-8aC), 130.88
(ph-1C), 129.17 (ph-2,6C), 129.10 (tetr-5C), 121.67 (tetr-6C),
114.60 (ph-3,5C), 110.11 (tetr-8C), 69.41 (prop-1C), 67.55 (ph-
CH2), 57.84 (prop-3C), 56.07 (pip-2,6C), 38.34 (tetr-2C), 30.42
(tetr-4C), 27.88 (prop-2C), 26.09 (pip-3,5C), 24.95 (pip-4C),
23.14 (tetr-3C).
ESI MS: 394.7 [M+H+] (100).
HRMS: calc.: 394.23767; found: 394.23767.
Compound 9
(E)-2-(4-(Dimethylamino)benzylidene)-6-(4-(3-(piperidin-1-yl)
propoxy)benzyloxy)-1-tetralone. Compound 7 (300mg,
0.8mmol) and 4-(dimethylamino)benzaldehyde (113, 0.8mmol)
were dissolved in 3mL ethanol. 15M NaOH (0.2mL) was added.
The mixture was stirred over night at room temperature, con-
centrated to dryness, and puriﬁed by column chromatography
(CH2Cl2/MeOH, 9/1). Yellow solid, 357mg, 85%.
C34H40N2O3
Molecular Weight: 524.7
1H NMR (250MHz, DMSO-d6) δ 7.89 (d, J = 7.5, 1H, tetr-
8H ), 7.61 (s, 1H, benzylid-2H ), 7.43–7.37 (m, 4H, dmab-2,6H,
ph-2,6H ), 7.04–6.96 (m, 4H, tetr-7H, ph-3,5H, tetr-5H ), 6.74 (d,
J = 7.5, 2H, dmab-3,5H ), 5.10 (s, 2H, ph-CH2), 4.02 (t, J = 5,
2H, prop-1H2), 3.07 (t, J = 7.5, 2H, tetr-3H2), 2.97 (s, 6H, dmab-
N(CH3)2), 2.85 (t, J = 7.5, 2H, tetr-4H2), 2.68–2.61(m, 6H, prop-
3H2, pip-2,6H2), 1.99 (q, J = 5, 2H, pip-2H2), 1.62–1.58 (m, 4H,
pip-3,5H 2), 1.48–1.38 (m, 2H, pip-4H2).
13C NMR (63MHz, DMSO-d6) δ 185.13 (tetr-1C), 162.03
(tetr-6C), 158.31 (ph-4C), 150.38 (dmab-4C), 145.37 (tetr-2C),
136.27 (benzylid-2C), 132.01 (tetr-8aC), 131.79 (dmab-2,6C),
130.70 (tetr-8C), 130.55 (ph-2,5C), 129.61 (ph-1C), 126.79 (tetr-
4aC), 122.64 (dmab-1C), 114.40 (ph-3,5C), 113.06 (tetr-5C),
111.65 (dmab-3,5C), 110.94 (tetr-7C), 69.22 (prop-1C), 65.50
(ph-CH2), 54.35 (prop-3C), 53.21 (pip-2,6C), 40.13 (N(CH3)2),
28.17 (tetr-4C), 26.79 (prop-2C), 24.97 (pip-4C), 24.22 (pip-
3,5C), 22.86 (tetr-3C).
ESI MS: 525.5 [M+H+] (100).
HRMS: calc.: 525.31117; found: 525.31034.
Compound 10
(E)-2-(4-(Dimethylamino)benzylidene)-7-(4-(3-(piperidin-1-yl)
propoxy)benzyloxy)-1-tetralone. Compound 8 (60mg,
0.2mmol) and4-(dimethylamino)benzaldehyde (23mg,0.2mmol)
were dissolved in 1.5mL ethanol. 15M NaOH (0.04mL) was
added. The mixture was stirred over night at room temperature,
concentrated to dryness, and puriﬁed by column chromatography
(CH2Cl2/MeOH, 9/1). Yellow solid, 72mg, 91%.
C34H40N2O3
Molecular weight: 524.7
1H NMR (250MHz, DMSO-d6) δ 7.58 (s, 1H, benzylid-2H ),
7.41 (d, J = 5, 2H, dmab-3,5H ), 7.36 (d, J = 5, 2H, ph-2,6H ), 7.31
(s, 1H, tetr-8H ), 7.23 (d, J = 7.5, 1H, tetr-5H ), 7.14 (d, J = 7.5, 1H,
tetr-6H),6.90 (d, J = 7.5, 2H,ph-3,5H ), 6.72 (d, J = 10,2H,dmab-
3,5H ), 5.01 (s, 2H, ph-CH2), 3.97 (t, J = 5, 2H, prop-1H2), 3.02 (t,
J= 5, 2H, tetr-3H2), 2.92 (s, 6H, dmab-N(CH3)2), 2.89 (t, J = 7.5,
2H, tetr-4H2), 2.84–2.78 (m, 6H, prop-3H2, pip-2,6H 2), 1.99 (q,
J = 5, 2H, prop-2H2), 1.66–1.60 (m, 4H, pip-3,5H 2), 1.42–1.33
(m, 2H, pip-4H 2).
13C NMR (63MHz,DMSO-d6) δ 185.93 (tetr-1C), 158.30 (ph-
4C), 157.28 (tetr-7C), 150.98 (dmab-4C), 137.16 (benzylid-2C),
135.54 (tetr-2C), 134.52 (tetr-8aC), 132.01 (dmab-2,6C), 130.43
(tetr-4aC), 129.75 (tetr-5C), 129.48 (ph-2,6C), 129.13 (ph-1C),
122.73 (dmab-1C), 120.70 (tetr-6C), 114.81 (ph-3,5C), 111.69
(dmab-3,5C), 110.80 (tetr-8C), 69.50 (prop-1C), 65.43 (ph-CH2),
55.73 (prop-3C), 53.04 (pip-2,6C), 39.62 (dmab-N(CH3)3), 28.24
(tetr-4C), 27.78 (prop-2C), 27.03 (pip-3,5C), 24.58 (pip-4C),
23.94 (tetr-3C).
ESI MS: 525.8 [M+H+] (100).
HRMS: calc.: 525.31117; found: 525.31129.
Compound 11
(E)-2-((E)-3-(4-(Dimethylamino)phenyl)allylidene)-6-(4-(3-
(piperidin-1-yl)propoxy)benzyloxy)-1-tetralone. Compound 7
(300mg, 0.8mmol) and 4-(dimethylamino)cinnamic aldehyde
(133mg, 0.8mmol) were dissolved in 5mL ethanol. 15M NaOH
(0.22mL) was added. The mixture was stirred over night at
room temperature, concentrated to dryness, and puriﬁed by col-
umn chromatography (CH2Cl2/MeOH,9/1).Yellow solid, 398mg,
95%.
C36H42N2O3
Molecular Weight: 550.7
1HNMR (250MHz,DMSO-d6) δ 7.96 (d, J = 10, 1H, tetr-8H ),
7.57 (d, J = 7.5, 2H, ph-2,6H ), 7.48 (d, J = 7.5, 2H, dmap-2,6H ),
7.40 (d, J = 16, 1H, allylid-2H), 7.14–7.01 (m,6H,ph-3,5H, dmap-
3,5H, tetr-5H, tetr-7H ), 6.84 (t, J = 16, 1H, allylid-3H ), 6.79 (d,
J = 16, 1H, allylid-4H ), 5.19 (s, 2H, ph-CH2), 4.11 (t, J = 6.3,
2H, prop-1H2), 3.56–3.42 (m, 6H, prop-3H2, pip-2,6H2), 3.12–
3.05 (m, 2H, tetr-3H2), 3.03 (s, 6H, N(CH3)2), 2.18 (q, J = 4.7,
2H, pip-2H2), 1.81–1.76 (m, 4H, pip-3,5H 2), 1.65–1.59 (m, 2H,
pip-4H2).
13C NMR (63MHz, DMSO-d6) δ 184.91 (tetr-1C), 162.19
(tetr-6C), 158.09 (ph-4C), 151.02 (dmap-4C), 145.99 (tetr-
8aC), 141.89 (allylid-2C), 136.49 (allylid-4C), 131.56 (tetr-2C),
129.79 (ph-2,6C), 128.89 (ph-1C),128.86 (tetr-8C), 127.37 (tetr-
4aC), 124.39 (dmap-1,2,6C), 119.17 (allylid-3C), 114.89 (ph-
3,5C), 114.15 (dmap-3,5C), 113.40 (tetr-5C), 111.91 (tetr-7C),
69.46 (prop-1C), 65.36 (ph-CH2), 53.81 (prop-3C), 52.70 (pip-
2,6C), 40.22 (N(CH3)2), 28.30 (tetr-4C), 25.70 (pip-3,5C), 24.21
(prop-2C), 23.09 (pip-4C), 21.60 (tetr-3C).
ESI MS: 551.4 [M+H+] (100).
HRMS: calc.: 551.32682; found: 551.32618.
Compound 12
(E)-2-((E)-3-(4-(Dimethylamino)phenyl)allylidene)-7-(4-(3-
(piperidin-1-yl)propoxy)benzyloxy)-1-tetralone. Compound 8
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(60mg, 0.2mmol) and 4-(dimethylamino)cinnamic aldehyde
(27mg, 0.2mmol) were dissolved in 1.5mL ethanol. 15M NaOH
(0.04mL) was added. The mixture was stirred over night at room
temperature, concentrated to dryness, and puriﬁed by column
chromatography (CH2Cl2/MeOH, 9/1). Yellow solid, 77mg, 93%.
C36H42N2O3
Molecular Weight: 550.7
1H NMR (250MHz, DMSO-d6) δ 7.59 (d, J = 16, 1H, allylid-
2H ), 7.54 (d, J = 7.5, 2H, dmap-2,6H ), 7.47 (d, J = 5, 2H, ph-
2,6H ), 7.38 (s, 1H, tetr-8H ), 7.35 (d, J = 5, 1H, tetr-5H ), 7.29
(d, J = 10, 1H, tetr-6H), 7.17 (d, J = 16, 1H, allylid-3H ), 7.04 (d,
J = 10, 2H, ph-3,5H ), 6.86 (t, J = 16, 1H, allylid-3H ), 6.80 (d,
J = 10, 2H, dmap-3,5H ), 5.14 (s, 2H, ph-CH2), 4.11 (t, J = 6.25,
2H, prop-1H2), 3.18 (t, J= 5, 2H, tetr-3H2), 3.03 (s, 6H, dmap-
N(CH3)2), 2.97 (t, J = 7.5, 2H, tetr-4H2), 2.95–2.81 (m, 6H, prop-
3H2, pip-2,6H 2), 2.15 (q, J = 5, 2H, prop-2H2), 1.85–1.77 (m, 4H,
pip-3,5H 2), 1.60–1.45 (m, 2H, pip-4H 2).
13C NMR (63MHz, DMSO-d6) δ 183.03 (tetr-1C), 158.34
(ph-4C), 157.83 (tetr-7C), 150.38 (dmap-4C), 141.18 (allylid-
2C), 138.52 (allylid-4C), 135.46 (tetr-2C), 133.62 (tetr-8aC),
131.08 (dmap-2,6C), 129.63 (tetr-4aC), 129.88 (tetr-5C), 129.84
(ph-2,6C), 128.31 (ph-1C), 125.34 (allylid-3C), 124.71 (dmap-
1C), 120.63 (tetr-6C), 114.62 (ph-3,5C), 114.92 (tetr-8C), 111.76
(dmap-3,5C), 73.58 (prop-1C), 70.44 (ph-CH2), 56.35 (prop-
3C), 54.47 (pip-2,6C), 39.89 (dmap-N(CH3)3), 28.56 (tetr-
4C), 27.85 (prop-2C), 25.83 (pip-3,5C), 24.83 (pip-4C), 23.45
(tetr-3C).
ESI MS: 551.8 [M+H+] (100).
HRMS: calc.: 551.32682; found: 551.32705.
FLUORESCENCE CHARACTERIZATION
FIGUREA1 | Fluorescence emission spectra of chalcone derivatives in
logarithmic delineation (Excitation wavelength: 405nm).
FIGUREA2 | Fluorescence emission spectra of chalcone derivatives
(Excitation wavelength: 405nm).
FIGUREA3 | Fluorescence emission spectra of chalcone derivatives
with O-alkyl-ether as spacer B (Excitation wavelength: 405nm).
SELECTIVITY DATA
FIGUREA4 | Graphic chart of human histamine H1, H3, and H4 receptor
pK i values.
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Table A1 | Fluorescence images of fluorescent compounds.
Compound Cell line Ligand image DAPI image Overlay of ligand and DAPI image
3 hH3-HEK-293
3 HEK-293
4 hH3-HEK-293
4 HEK-293
5 hH3-HEK-293
5 HEK-293
(Continued)
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Table A1 | Continued
Compound Cell line Ligand image DAPI image Overlay of ligand and DAPI image
6 hH3-HEK-293
6 HEK-293
9 hH3-HEK-293
9 HEK-293
10 hH3-HEK-293
10 HEK-293
(Continued)
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Table A1 | Continued
Compound Cell line Ligand image DAPI image Overlay of ligand and DAPI image
11 hH3-HEK-293
11 HEK-293
12 hH3-HEK-293
12 HEK-293
– H3-HEK-293
– HEK-293
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